Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2011 2
2012 2
2013 4
2014 3
2015 1
2016 3
2017 1
2018 2
2019 6
2020 4
2021 10
2022 9
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
A surveillance study of SARS-CoV-2 infection in immunosuppressed patients.
Bradshaw D, Harrison K, Page E, Taha Y, Killip M, Parkes S, Lloyd C, Kokocinska M, Davies K, Beetar-King T, Zambon M, Kelly D. Bradshaw D, et al. J Infect Prev. 2024 Mar;25(1-2):38-40. doi: 10.1177/17571774241226584. Epub 2024 Jan 16. J Infect Prev. 2024. PMID: 38362110 No abstract available.
Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease.
Bradshaw D, Abramowicz I, Bremner S, Verma S, Gilleece Y, Kirk S, Nelson M, Housman R, Miras H, Orkin C, Fox A, Curnock M, Jennings L, Gompels M, Clarke E, Robinson R, Lambert P, Chadwick D, Perry N. Bradshaw D, et al. PLoS One. 2023 Jul 14;18(7):e0288598. doi: 10.1371/journal.pone.0288598. eCollection 2023. PLoS One. 2023. PMID: 37450478 Free PMC article. Clinical Trial.
Characterization of Rare Spontaneous Human Immunodeficiency Virus Viral Controllers Attending a National United Kingdom Clinical Service Using a Combination of Serology and Molecular Diagnostic Assays.
Khan M, Bradshaw D, Brown CS, Haddow J, Patel P, Tosswill JHC, Pollock K, Elliott T, Wang X, Alagaratnam J, Mora-Peris B, Kaye S, McClure MO, Muir D, Randell P, Taylor GP, Fidler SJ. Khan M, et al. Among authors: bradshaw d. Open Forum Infect Dis. 2023 Mar 1;10(5):ofad108. doi: 10.1093/ofid/ofad108. eCollection 2023 May. Open Forum Infect Dis. 2023. PMID: 37152187 Free PMC article.
Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial.
Desmarets M, Hoffmann S, Vauchy C, Rijnders BJA, Toussirot E, Durrbach A, Körper S, Schrezenmeier E, van der Schoot CE, Harvala H, Brunotte G, Appl T, Seifried E, Tiberghien P, Bradshaw D, Roberts DJ, Estcourt LJ, Schrezenmeier H. Desmarets M, et al. Among authors: bradshaw d. BMJ Open. 2023 Apr 27;13(4):e071277. doi: 10.1136/bmjopen-2022-071277. BMJ Open. 2023. PMID: 37105693 Free PMC article.
HTLV seroprevalence in people using HIV pre-exposure prophylaxis in England.
Bradshaw D, Khawar A, Patel P, Tosswill J, Brown C, Ogaz D, Mason E, Osman R, Mitchell H, Dosekun O, Peris BM, Pickard G, Rayment M, Jones R, Hopkins M, Williams A, Kingston M, Machin N, Taha Y, Duncan S, Turner N, Gill N, Andrews N, Raza M, Tazzyman S, Nori A, Cunningham E, Taylor GP. Bradshaw D, et al. J Infect. 2023 Mar;86(3):245-247. doi: 10.1016/j.jinf.2023.01.033. Epub 2023 Feb 10. J Infect. 2023. PMID: 36773896 Free article.
Author Correction: SARS-CoV-2 evolution during treatment of chronic infection.
Kemp SA, Collier DA, Datir RP, Ferreira IATM, Gayed S, Jahun A, Hosmillo M, Rees-Spear C, Mlcochova P, Lumb IU, Roberts DJ, Chandra A, Temperton N; CITIID-NIHR BioResource COVID-19 Collaboration; COVID-19 Genomics UK (COG-UK) Consortium; Sharrocks K, Blane E, Modis Y, Leigh KE, Briggs JAG, van Gils MJ, Smith KGC, Bradley JR, Smith C, Doffinger R, Ceron-Gutierrez L, Barcenas-Morales G, Pollock DD, Goldstein RA, Smielewska A, Skittrall JP, Gouliouris T, Goodfellow IG, Gkrania-Klotsas E, Illingworth CJR, McCoy LE, Gupta RK. Kemp SA, et al. Nature. 2022 Aug;608(7922):E23. doi: 10.1038/s41586-022-05104-2. Nature. 2022. PMID: 35864233 Free PMC article. No abstract available.
Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
Collier DA, De Marco A, Ferreira IATM, Meng B, Datir RP, Walls AC, Kemp SA, Bassi J, Pinto D, Silacci-Fregni C, Bianchi S, Tortorici MA, Bowen J, Culap K, Jaconi S, Cameroni E, Snell G, Pizzuto MS, Pellanda AF, Garzoni C, Riva A; CITIID-NIHR BioResource COVID-19 Collaboration; Elmer A, Kingston N, Graves B, McCoy LE, Smith KGC, Bradley JR, Temperton N, Ceron-Gutierrez L, Barcenas-Morales G; COVID-19 Genomics UK (COG-UK) Consortium; Harvey W, Virgin HW, Lanzavecchia A, Piccoli L, Doffinger R, Wills M, Veesler D, Corti D, Gupta RK. Collier DA, et al. Nature. 2022 Aug;608(7922):E24. doi: 10.1038/s41586-022-05103-3. Nature. 2022. PMID: 35864232 Free PMC article. No abstract available.
PrEP use and unmet PrEP-need among men who have sex with men in London prior to the implementation of a national PrEP programme, a cross-sectional study from June to August 2019.
Ogaz D, Logan L, Curtis TJ, McDonagh L, Guerra L, Bradshaw D, Patel P, Macri C, Murphy G, Noel Gill O, Johnson AM, Nardone A, Burns F. Ogaz D, et al. Among authors: bradshaw d. BMC Public Health. 2022 Jun 3;22(1):1105. doi: 10.1186/s12889-022-13425-0. BMC Public Health. 2022. PMID: 35659209 Free PMC article.
Genomic assessment of quarantine measures to prevent SARS-CoV-2 importation and transmission.
Aggarwal D, Page AJ, Schaefer U, Savva GM, Myers R, Volz E, Ellaby N, Platt S, Groves N, Gallagher E, Tumelty NM, Le Viet T, Hughes GJ, Chen C, Turner C, Logan S, Harrison A; COVID-19 Genomics UK (COG-UK) Consortium; Peacock SJ, Chand M, Harrison EM. Aggarwal D, et al. Nat Commun. 2022 Feb 23;13(1):1012. doi: 10.1038/s41467-022-28371-z. Nat Commun. 2022. PMID: 35197443 Free PMC article.
46 results